List of Excipients in Branded Drug CLINDAMYCIN PHOSPHATE AND TRETINOIN GEL 1.2%/0.025%

« Back to Dashboard

Generic Drugs Containing CLINDAMYCIN PHOSPHATE AND TRETINOIN GEL 1.2%/0.025%

Company	Ingredient	NDC	Excipient
Encube Ethicals Inc	clindamycin phosphate and tretinoin gel 1.2%/0.025%	21922-050	ANHYDROUS CITRIC ACID
Encube Ethicals Inc	clindamycin phosphate and tretinoin gel 1.2%/0.025%	21922-050	BUTYLATED HYDROXYTOLUENE
Encube Ethicals Inc	clindamycin phosphate and tretinoin gel 1.2%/0.025%	21922-050	CARBOMER HOMOPOLYMER TYPE C
Encube Ethicals Inc	clindamycin phosphate and tretinoin gel 1.2%/0.025%	21922-050	EDETATE DISODIUM

What are the Most Frequently-Used Excipients in CLINDAMYCIN PHOSPHATE AND TRETINOIN GEL 1.2%/0.025%?

# Of NDCs	Excipient
1	ANHYDROUS CITRIC ACID
1	BUTYLATED HYDROXYTOLUENE
1	CARBOMER HOMOPOLYMER TYPE C
1	EDETATE DISODIUM

Clindamycin Phosphate and Tretinoin Gel 1.2%/0.025%: Excipient Strategy and Commercial Opportunities

Last updated: October 2, 2026

Clindamycin phosphate and tretinoin gel 1.2%/0.025% is a mature prescription acne combination with a relatively simple aqueous gel platform. The reference product, Ziana, combines topical antibiotic activity with a retinoid in a formulation containing carbomer 934P, methylparaben, polysorbate 80, propylene glycol, and purified water.[1] Its commercial opportunity is primarily post-exclusivity generic supply, differentiated packaging, improved tolerability, and potentially reformulated products that address irritation, stability, and adherence.

The main formulation challenge is balancing tretinoin stability and skin delivery against clindamycin compatibility, preservative performance, rheology, and patient irritation. The main commercial risk is declining use of topical antibiotic monotherapy and increasing pressure to pair antibiotic treatment with benzoyl peroxide to reduce antimicrobial resistance.[2]

What is the formulation of clindamycin phosphate and tretinoin gel?

The reference formulation uses the following excipient system:

Component	Function in the gel	Commercial relevance
Carbomer 934P	Gelling agent and viscosity modifier	Controls spreadability, residence time, and product feel
Methylparaben	Preservative	Supports microbiological control in the aqueous vehicle
Polysorbate 80	Surfactant and solubilization aid	Helps distribute hydrophobic tretinoin and other formulation components
Propylene glycol	Humectant, solvent, and penetration-supporting vehicle	Affects hydration, skin feel, and possible irritation
Purified water	Continuous phase	Provides the aqueous gel vehicle
Clindamycin phosphate	Water-soluble antibiotic prodrug	Delivered as clindamycin after topical application
Tretinoin	Retinoid active ingredient	Provides comedolytic and keratinization-normalizing activity

Ziana contains clindamycin phosphate equivalent to 1.2% clindamycin and tretinoin at 0.025%.[1] The product is indicated for acne vulgaris in patients 12 years and older.[1]

Clindamycin phosphate is relatively compatible with an aqueous phase. Tretinoin is poorly water-soluble and creates the greater formulation burden. The formulation therefore requires controlled dispersion or solubilization, protection from degradation, and consistent dose delivery across the product shelf life.

How does each excipient affect product performance?

Carbomer 934P

Carbomer establishes the three-dimensional polymer network that gives the product its gel structure. Its concentration and neutralization state affect:

• Viscosity
• Spreadability
• Skin residence time
• Tube or pump extrusion force
• Phase stability
• Dose uniformity

A higher-viscosity gel may improve retention on the face but can feel tacky or difficult to spread. A lower-viscosity system may improve cosmetic acceptance but increase runoff and dosing variability.

Carbomer grade selection also affects manufacturing robustness. Changes in polymer molecular weight, neutralization level, mixing order, or shear can alter the final rheology without changing the nominal ingredient list. These changes can create comparability problems for an abbreviated new drug application if the reference product has a narrow quality profile.

Polysorbate 80

Polysorbate 80 can improve wetting and dispersion of tretinoin and help stabilize the formulation. Its concentration must be controlled because excess surfactant can increase irritation, alter drug partitioning into the skin, or change the product's sensory profile.

Polysorbate 80 also requires control of peroxide and degradation impurities. Oxidative impurities can be relevant in formulations containing oxidation-sensitive ingredients such as tretinoin. Supplier qualification and incoming-material specifications are therefore part of the active pharmaceutical ingredient and excipient control strategy.

Propylene glycol

Propylene glycol can function as a humectant and solvent. It may increase hydration of the stratum corneum and influence tretinoin delivery. Its concentration is commercially important because it can affect:

• Burning and stinging
• Dryness
• Tackiness
• Evaporation rate
• Patient adherence

A lower-irritation vehicle could support premium positioning, but changing the propylene glycol level may change bioavailability, local tolerability, and comparative quality attributes.

Methylparaben

Methylparaben provides preservation in the water-based gel. Its concentration must be sufficient to pass antimicrobial effectiveness testing while remaining compatible with the formulation and packaging.

A preservative-free product could have commercial appeal for patients concerned about preservatives, but it would require a different microbiological control strategy. Options could include a single-use package, airless pump, sterile manufacturing approach, or a validated low-bioburden system. These approaches would raise manufacturing and packaging costs and may require additional regulatory justification.

What formulation properties matter most for generic approval?

For an ANDA, the highest-value formulation targets are usually qualitative and quantitative sameness, physical stability, drug content, impurity control, microbiological quality, and comparative performance.

Quality attribute	Why it matters
Assay of clindamycin and tretinoin	Confirms labeled strength
Content uniformity	Controls dose consistency across the container
Viscosity and rheology	Influences application, residence time, and product performance
Particle or droplet distribution	Relevant to tretinoin dispersion and skin delivery
pH	Affects stability, preservative performance, and skin tolerability
In vitro release	Helps demonstrate comparable release behavior
Microbial limits	Required for an aqueous topical product
Preservative effectiveness	Confirms protection during use
Tube or pump delivery	Affects delivered dose and usability
Stability under light and heat	Critical for tretinoin and overall shelf life

The reference product's qualitative and quantitative composition is a useful starting point, but copying the ingredient list alone does not ensure equivalent product performance. A generic developer must control process parameters such as carbomer hydration, mixing shear, deaeration, order of addition, and filling conditions.

What excipient strategies can differentiate the product?

Lower-irritation gel

The most direct opportunity is a formulation with lower stinging, dryness, and visible flaking. Potential levers include:

• Optimizing propylene glycol concentration
• Using a lower-irritation surfactant system
• Narrowing pH toward the best tolerability range
• Improving tretinoin dispersion
• Reducing local concentration spikes during application
• Modifying gel viscosity to improve uniform spreading

A tolerability claim would require clinical or comparative support. It cannot be assumed from excipient substitution alone.

Improved tretinoin stabilization

Tretinoin is vulnerable to degradation from light, oxygen, and formulation conditions. Commercial opportunities include:

• Opaque or UV-protective packaging
• Lower-oxygen headspace
• Airless pump delivery
• Antioxidant systems, if compatible with the reference product and regulatory pathway
• Improved control of trace metals and peroxide impurities
• Tighter manufacturing and storage specifications

Packaging may provide a faster route to stability improvement than major vehicle reformulation. It can also support premium positioning without changing the active ingredient ratio.

Airless pump or metered-dose package

The reference product is supplied in a topical container. A metered-dose pump could improve dose reproducibility, reduce finger contamination, and limit exposure to oxygen and light. The key development requirements would include:

• Priming and re-priming performance
• Dose uniformity through end of life
• Compatibility of the gel with pump components
• Container closure integrity
• Extractables and leachables
• Residual product and waste
• Usability for adolescent and adult patients

A package change that does not alter the formulation may be suitable for a supplement or a separate regulatory strategy, depending on the product and the nature of the claims.

Preservative-free presentation

A preservative-free presentation could target sensitive-skin patients and dermatology practices. The business case is strongest if the product uses a single-dose or highly protective package. The weaknesses are higher packaging cost, more complicated manufacturing, and possible loss of convenience compared with a multidose tube.

Improved cosmetic profile

Acne patients often discontinue products because of greasiness, tackiness, pilling, or visible residue. A thinner, faster-spreading gel with reduced tack could improve adherence. This opportunity is commercially meaningful, but changes to surfactants, solvents, or rheology modifiers may affect skin delivery and regulatory comparability.

What regulatory pathway applies to a generic version?

A conventional generic would generally use the ANDA pathway under section 505(j) of the Federal Food, Drug, and Cosmetic Act. The developer would seek approval based on equivalence to the reference listed drug, including pharmaceutical equivalence and applicable bioequivalence requirements.[3]

A materially reformulated product could require a 505(b)(2) application rather than an ANDA. This is more likely where the sponsor changes:

• Active ingredient concentration
• Dosage form
• Delivery system
• Route or site of administration
• Clinical use
• Formulation in a way that affects product performance or safety

An improved package, preservative system, or vehicle may still be possible within a generic strategy, but the regulatory classification depends on the specific change and its effect on equivalence.

When did clindamycin phosphate and tretinoin gel lose exclusivity?

The reference product was approved by FDA as Ziana under NDA 050783. Its original commercial exclusivity and the principal patent barriers are no longer the primary obstacles to entry. The product is in a mature post-exclusivity market, with generic products available or historically marketed under the clindamycin phosphate and tretinoin topical gel designation.[1,4]

Regulatory issue	Commercial assessment
New chemical entity exclusivity	Not a current barrier
Original NDA exclusivity	Expired
Active Orange Book barrier	Must be confirmed against the current FDA listing before launch
Paragraph IV exposure	Relevant historically and for any remaining listed patent
Generic entry	Primarily governed by formulation equivalence, manufacturing scale, price, and channel access
Biosimilar risk	Not applicable because this is a small-molecule topical drug

Because Orange Book patent listings and marketing status can change, launch planning should use the current FDA Orange Book record for NDA 050783 and any applicable ANDA records.[4]

What patent protection covers the product?

The historic patent estate for clindamycin phosphate and tretinoin gel centered on the combination product, its composition, and related topical use. The practical value of that estate has declined because the product has moved beyond its original exclusivity period.

The most relevant patent categories are:

Patent category	Relevance to a current entrant
Combination composition patents	Historically protected the clindamycin-tretinoin combination
Gel vehicle patents	Could cover polymer, solvent, surfactant, or preservative combinations
Method-of-use patents	Could cover treatment of acne or specific patient populations
Packaging patents	May protect airless, metered, or light-protective delivery systems
Process patents	Could cover mixing, dispersion, or manufacturing steps
Formulation-improvement patents	Potential route for new lifecycle products

A developer should not assume that an expired combination patent eliminates all risk. A newer formulation, package, manufacturing process, or method-of-use patent could create a separate barrier. The relevant analysis is claim-specific and depends on the current patent register, Orange Book listing, prosecution history, and litigation record.

Are Paragraph IV challenges and patent litigation still material?

Paragraph IV certification is most relevant if an ANDA applicant asserts that a listed patent is invalid, unenforceable, or not infringed. For a mature topical combination product, the greater commercial risk often shifts from patent litigation to regulatory delay, bioequivalence failure, manufacturing scale-up, and price erosion.

A Paragraph IV strategy can still be valuable when:

• A listed patent remains unexpired
• The patent covers a commercially important formulation or use
• The applicant has a credible noninfringement or invalidity position
• The first-filer economics justify litigation exposure

For this product, current litigation status should be reviewed through FDA Orange Book records, federal court dockets, and patent assignment records. The product does not carry biosimilar litigation risk because clindamycin and tretinoin are small molecules, not biologics.

How strong is the formulation patent estate?

The formulation estate is moderate to weak for a standard generic gel but can be stronger for an improved delivery system. A basic carbomer, propylene glycol, polysorbate 80, methylparaben, and water vehicle is relatively accessible from a formulation standpoint. Defensibility may improve through:

• Narrow excipient ranges linked to measured performance
• Tretinoin particle engineering
• Controlled-release or reduced-irritation delivery
• Airless or metered-dose packaging
• Stability improvements with demonstrated shelf-life benefit
• Manufacturing controls that produce a distinctive microstructure
• Clinical evidence linking the formulation to improved tolerability or adherence

Broad excipient substitution patents are often difficult to defend if the claimed ingredients are conventional. Stronger protection usually requires a defined technical effect supported by comparative data.

What commercial opportunities exist for manufacturers?

Commodity generic

The lowest-cost strategy is a conventional ANDA using a close reference formulation. Success depends on:

• Reliable API supply
• Low-cost tube filling
• High batch yields
• Stable viscosity and content uniformity
• Wholesale and pharmacy access
• Contracting with managed-care plans

Margins can compress rapidly as multiple suppliers enter.

Premium generic

A premium generic can compete through packaging, tolerability, supply reliability, or dermatology-focused promotion. Potential differentiators include:

• Airless pump
• Smaller or travel-size package
• Better patient instructions
• Dermatology office distribution
• Lower-tack gel
• Packaging designed to reduce light exposure

The premium is more defensible when supported by measurable usability or stability data.

505(b)(2) reformulation

A 505(b)(2) product could target reduced irritation, improved adherence, longer shelf life, or a new delivery system. Development cost and regulatory complexity would be higher than for an ANDA, but the product could support differentiated pricing and new intellectual property.

Contract manufacturing and private label

The formulation is suitable for dermatology-focused private-label programs and regional generic suppliers. Contract manufacturers with high-quality semisolid capabilities can offer:

• Formulation development
• Analytical method transfer
• Tube and pump filling
• Stability programs
• ANDA support
• Smaller commercial batches

Supply reliability is a meaningful competitive factor because topical dermatology products have experienced periodic shortages and channel disruptions.

How does this product compare with alternative acne combinations?

Product type	Advantages	Limitations
Clindamycin/tretinoin gel	Combines antibiotic and retinoid treatment in one product	Irritation, antibiotic resistance, prescription cost
Clindamycin/benzoyl peroxide	Better resistance-management profile than clindamycin alone	Can cause dryness, bleaching, and packaging-stability challenges
Adapalene/benzoyl peroxide	Non-antibiotic combination with strong maintenance utility	May be irritating and may carry higher branded competition
Tretinoin monotherapy	No antibiotic resistance issue; multiple strengths and vehicles	Does not provide antibacterial activity
Azelaic acid products	Useful for acne and post-inflammatory hyperpigmentation	May have slower perceived results and cosmetic limitations
Oral antibiotics plus topical retinoid	Useful for more inflammatory disease	Greater systemic exposure and stewardship concerns

The commercial position of clindamycin/tretinoin is strongest where prescribers value single-product convenience and the patient needs both antibacterial and retinoid treatment. Its position is weaker where guidelines prioritize benzoyl peroxide-containing regimens or antibiotic-sparing maintenance therapy.[2]

What generic launch scenarios are most likely?

Low-price multiple-generic entry

Several suppliers enter with close-copy gel products. Prices decline, pharmacy substitution increases, and differentiation becomes limited to availability and contracting.

One differentiated generic

A manufacturer launches a pump or improved package and secures dermatology-channel adoption. The product retains a modest premium if the delivery system improves adherence or reduces waste.

Reformulated lifecycle product

A sponsor develops a lower-irritation or stability-enhanced product under a 505(b)(2) strategy. The product can obtain new formulation patents but must prove that the technical improvement is clinically or commercially meaningful.

Declining category

Use declines as clinicians limit topical antibiotic exposure and favor benzoyl peroxide or non-antibiotic maintenance therapies. In this scenario, manufacturing efficiency matters more than aggressive formulation investment.

What manufacturing and intellectual-property barriers matter most?

The main manufacturing barriers are process control and semisolid scale-up rather than unusual raw-material complexity. Critical controls include:

• Carbomer hydration
• Dispersion of tretinoin
• Control of oxygen and light exposure
• Final pH adjustment
• Viscosity consistency
• Deaeration
• Filling accuracy
• Tube or pump compatibility
• Microbial control

The main intellectual-property opportunity is a demonstrated formulation improvement. A generic copy has limited defensibility. A product that improves dose delivery, stability, tolerability, or adherence has a stronger basis for differentiated protection.

Key Takeaways

• Clindamycin phosphate and tretinoin gel 1.2%/0.025% uses a conventional aqueous carbomer gel with methylparaben, polysorbate 80, propylene glycol, and purified water.
• Tretinoin stability, dispersion, light protection, and irritation control are the principal formulation priorities.
• The product is a mature post-exclusivity opportunity; generic entry is driven more by equivalence, cost, supply, and channel access than by original exclusivity.
• A conventional ANDA offers the lowest development risk but limited pricing power.
• Airless packaging, improved dose delivery, lower tack, and reduced irritation are the strongest commercial differentiation routes.
• A materially improved vehicle or delivery system may require a 505(b)(2) strategy and could support new formulation patents.
• The principal clinical-commercial risk is declining use of topical antibiotic regimens and increased preference for benzoyl peroxide-containing or antibiotic-sparing acne treatment.
• Biosimilar risk does not apply because the product contains small-molecule active ingredients.

FAQs

Is clindamycin phosphate and tretinoin gel still commercially attractive?

Yes, but mainly as a cost-efficient generic or differentiated dermatology product. The opportunity is weaker for an undifferentiated, high-cost launch.

Which excipient is most important for tretinoin delivery?

Polysorbate 80, propylene glycol, and the carbomer network collectively influence tretinoin dispersion and release. No single excipient determines performance independently.

Can a manufacturer remove methylparaben from the formulation?

Yes, technically, but a preservative-free presentation requires a new microbiological control and packaging strategy. It may also require a regulatory pathway different from a straightforward ANDA.

Is an airless pump patentable for this acne gel?

Potentially. Patent strength would depend on the claimed pump, formulation-package interaction, dose uniformity, stability improvement, or other measurable technical effect.

Does clindamycin resistance reduce the product's market opportunity?

Yes. Resistance concerns can reduce prescribing and favor benzoyl peroxide-containing regimens. A fixed combination that includes tretinoin remains commercially relevant, but stewardship expectations limit long-term antibiotic use.

References

1. U.S. Food and Drug Administration. (n.d.). Ziana (clindamycin phosphate and tretinoin) gel, 1.2%/0.025% prescribing information. Drugs@FDA.

2. American Academy of Dermatology Association. (2024). Guidelines of care for the management of acne vulgaris. Journal of the American Academy of Dermatology.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

4. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs database, NDA 050783. FDA.